Analytical Data
-
Gene name
ACP5
- Application
-
Alternative Names
ACP5；Tartrate-resistant acid phosphatase type 5
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P13686
-
Expression Region
22-325aa
-
AA Sequence
ATPALRFVAVGDWGGVPNAPFHTAREMANAKEIARTVQILGADFILSLGDNFYFTGVQDINDKRFQETFEDVFSDRSLRKVPWYVLAGNHDHLGNVSAQIAYSKISKRWNFPSPFYRLHFKIPQTNVSVAIFMLDTVTLCGNSDDFLSQQPERPRDVKLARTQLSWLKKQLAAAREDYVLVAGHYPVWSIAEHGPTHCLVKQLRPLLATYGVTAYLCGHDHNLQYLQDENGVGYVLSGAGNFMDPSKRHQRKVPNGYLRFHYGTEDSLGGFAYVEISSKEMTVTYIEASGKSLFKTRLPRRARP
-
Molecular Weight
35.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ACP5, also known as acid phosphatase 5, is a member of the acid phosphatase family, which plays a vital role in regulating various physiological processes, including bone resorption, immune response, and cellular signaling. Research into ACP5 has gained significant attention due to its involvement in pathological conditions such as osteoporosis and certain types of cancers. As a secretory glycoprotein, ACP5 is primarily produced by osteoclasts and is crucial for the degradation of phosphate esters, thus contributing to the mineralization of bone. Understanding the molecular structure and functional mechanisms of ACP5 can provide insights into its regulatory roles and potential therapeutic targets. Advances in recombinant DNA technology have facilitated the production of recombinant ACP5, enabling detailed studies of its enzymatic activity, substrate specificity, and interaction with other biomolecules. This research not only enhances our understanding of ACP5's role in physiology and pathology but also opens avenues for the development of novel treatments aimed at diseases associated with ACP5 dysregulation. As such, the exploration of ACP5 as a therapeutic target has become an important focus in biomedical research, particularly in conditions where bone metabolism is disrupted.
